MI-LINEAGE-LOGISTICS-LLC
Lineage Logistics, LLC (“Lineage” or the “Company”), one of the world’s leading temperature-controlled industrial REIT and logistics solutions providers, today officially opened its fully-automated Cool Port II cold storage facility in the Port of Rotterdam, Netherlands, adding a key European port location to Lineage’s global network of best-in-class cold storage facilities.
The fully automated deep-freeze high bay warehouse offers 60,000 pallet locations, three automated truck unloading systems and a full range of services to safely store food products and bring them to market. Strategically located in Europe’s largest sea port, the new Cool Port II facility co-located next to Cool Port I gives customers the option of tri-modal connections by sea, rail and road, connecting Lineage’s growing network from Europe to the UK and far beyond.
The facility features the industry’s most advanced automation solutions, helping to address labour volatility, provide fast and efficient service to clients and reduce the site’s energy consumption, all while ensuring the highest level of food safety and reduction of food waste. Cool Port II utilises data-driven solutions to optimise its energy use, with precision cooling cycles to minimise energy leakage and a high-rise design that maximises storage density and reduces the site’s energy footprint. Best-in-class refrigeration technology and the latest systems for temperature control combined with the energy-saving design of the facility make Cool Port II a frontrunner in energy efficiency in the cold storage sector. The site is up to 45% more energy efficient than a conventional cold storage facility.
“Our new Cool Port II facility highlights the best-in-class approach that makes Lineage a unique and forward-looking partner for our customers,” said Harld Peters, President of Europe at Lineage. “In addition to its strategic location, Cool Port II utilises the latest in automation technology. Our aim is to be a driving force behind greening the supply chain, investing in our people and our facilities to deploy the very latest in cold storage technology. In this way, we can reduce our energy footprint while providing the solutions our customers need to deliver food safely and efficiently throughout Europe and beyond.”
In addition to the increased energy efficiency of a fully automated facility, the building is constructed to meet the highest BREEAM sustainability standards. Cool Port has over 11,000 solar panels on its roof making Lineage one of the leading companies in the Port of Rotterdam when it comes to generating solar power for in-house use. As a Climate Pledge signatory, Lineage is committed to achieving net-zero carbon emissions across its operations by 2040.
“We are proud to open this state-of-the-art facility, a multi-modal facility that is well connected by road, rail and barges and the only cold store facility in Rotterdam connected with the Short Sea Terminals. We aim to provide Lineage’s customers easy access to a strong and growing network to deliver their product safely and efficiently,” said Mark Ketelaar, Regional Vice President for the Benelux Region at Lineage Logistics. “Cool Port II offers a complete range of services and state-of-the-art facilities to maximise efficiency and safe handling of the products in our care.”
In recent years Lineage has expanded its network across Europe, creating a one-stop-shop solution for customers across the continent. This reduces the complexity of moving food between countries, reduces food waste and makes the distribution of food more efficient and resilient.
About Lineage Logistics
Lineage Logistics is one of the world’s leading temperature-controlled industrial REIT and logistics solutions provider. It has a global network of over 400 strategically located facilities totalling over 2 billion cubic feet of capacity, which spans 20 countries across North America, Europe and Asia-Pacific. Lineage’s industry-leading expertise in end-to-end logistical solutions, its unrivalled real estate network and the development and deployment of innovative technology help increase distribution efficiency, advance sustainability, minimize supply chain waste and, most importantly, as a Visionary Partner of Feeding America, help feed the world. In recognition of the company’s leading innovations and sustainability initiatives, Lineage was No. 17 in the 2021 CNBC Disruptor 50 list, the No 1. Data Science company, and 23rd overall, on Fast Company’s 2019 list of The World’s Most Innovative Companies, in addition to being included on Fortune’s Change The World list in 2020. Lineage is a 2022 U.S. Best Managed Company, a recognition by Deloitte Private and The Wall Street Journal for private companies that demonstrate excellence in strategic planning and execution, corporate culture and financial results. (www.lineagelogistics.com)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221123005098/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
